Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.
PD-1
PD-L1
immunotherapy
meningioma
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
05 01 2022
05 01 2022
Historique:
pubmed:
21
5
2021
medline:
20
1
2022
entrez:
20
5
2021
Statut:
ppublish
Résumé
Programmed death ligand 1 (PD-L1) contributes to tumor immunosuppression and is upregulated in aggressive meningiomas. We performed a phase II study of nivolumab, a programmed death 1 (PD-1) blocking antibody among patients with grade ≥2 meningioma that recurred after surgery and radiation therapy. Twenty-five patients received nivolumab (240 mg biweekly) until progression, voluntary withdrawal, unacceptable toxicity, or death. Tumor mutational burden (TMB) and quantification of tumor-infiltrating lymphocytes (TIL) were evaluated as potential immunocorrelative biomarkers. Change in neurologic function was prospectively assessed using the Neurologic Assessment in Neuro-Oncology (NANO) scale. Enrolled patients had multiple recurrences including ≥3 prior surgeries and ≥2 prior courses of radiation in 60% and 72%, respectively. Nivolumab was well tolerated with no unexpected adverse events. Six-month progression-free survival (PFS-6) rate was 42.4% (95% CI: 22.8, 60.7) and the median OS was 30.9 months (95% CI: 17.6, NA). One patient achieved radiographic response (ongoing at 4.5 years). TMB was >10/Mb in 2 of 15 profiled tumors (13.3%). Baseline TIL density was low but increased posttreatment in 3 patients including both patients with elevated TMB. Most patients who achieved PFS-6 maintained neurologic function prior to progression as assessed by NANO. Nivolumab was well tolerated but failed to improve PFS-6, although a subset of patients appeared to derive benefit. Low levels of TMB and TIL density were typically observed. NANO assessment of neurologic function contributed to outcome assessment. Future studies may consider rationally designed combinatorial regimens.
Sections du résumé
BACKGROUND
Programmed death ligand 1 (PD-L1) contributes to tumor immunosuppression and is upregulated in aggressive meningiomas. We performed a phase II study of nivolumab, a programmed death 1 (PD-1) blocking antibody among patients with grade ≥2 meningioma that recurred after surgery and radiation therapy.
METHODS
Twenty-five patients received nivolumab (240 mg biweekly) until progression, voluntary withdrawal, unacceptable toxicity, or death. Tumor mutational burden (TMB) and quantification of tumor-infiltrating lymphocytes (TIL) were evaluated as potential immunocorrelative biomarkers. Change in neurologic function was prospectively assessed using the Neurologic Assessment in Neuro-Oncology (NANO) scale.
RESULTS
Enrolled patients had multiple recurrences including ≥3 prior surgeries and ≥2 prior courses of radiation in 60% and 72%, respectively. Nivolumab was well tolerated with no unexpected adverse events. Six-month progression-free survival (PFS-6) rate was 42.4% (95% CI: 22.8, 60.7) and the median OS was 30.9 months (95% CI: 17.6, NA). One patient achieved radiographic response (ongoing at 4.5 years). TMB was >10/Mb in 2 of 15 profiled tumors (13.3%). Baseline TIL density was low but increased posttreatment in 3 patients including both patients with elevated TMB. Most patients who achieved PFS-6 maintained neurologic function prior to progression as assessed by NANO.
CONCLUSION
Nivolumab was well tolerated but failed to improve PFS-6, although a subset of patients appeared to derive benefit. Low levels of TMB and TIL density were typically observed. NANO assessment of neurologic function contributed to outcome assessment. Future studies may consider rationally designed combinatorial regimens.
Identifiants
pubmed: 34015129
pii: 6279078
doi: 10.1093/neuonc/noab118
pmc: PMC8730772
doi:
Substances chimiques
B7-H1 Antigen
0
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-113Subventions
Organisme : NCI NIH HHS
ID : U54 CA225088
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Lancet Oncol. 2015 Nov;16(15):e534-e542
pubmed: 26545842
J Neuropathol Exp Neurol. 2021 Jan 20;80(2):150-159
pubmed: 33393633
Neuro Oncol. 2014 Jun;16(6):829-40
pubmed: 24500419
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
JCO Precis Oncol. 2019;3:
pubmed: 31832578
J Neurooncol. 2010 Sep;99(3):433-43
pubmed: 20730473
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
World Neurosurg. 2013 Nov;80(5):549-53
pubmed: 23871812
Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5
pubmed: 24234437
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
JAMA Oncol. 2019 Aug 1;5(8):1195-1204
pubmed: 31318407
Lancet Oncol. 2016 Sep;17(9):e383-91
pubmed: 27599143
J Neurooncol. 2016 Dec;130(3):543-552
pubmed: 27624915
Mol Cancer Ther. 2020 Oct;19(10):2139-2145
pubmed: 32747422
Nat Protoc. 2019 Oct;14(10):2900-2930
pubmed: 31534232
JCI Insight. 2019 Oct 17;4(20):
pubmed: 31536478
Oncotarget. 2015 Mar 10;6(7):4704-16
pubmed: 25609200
Elife. 2018 Jul 11;7:
pubmed: 29993362
World Neurosurg. 2018 Apr;112:e74-e83
pubmed: 29258946
J Clin Neurosci. 2018 Nov;57:149-151
pubmed: 30153998
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
J Neurosurg. 2015 Jan;122(1):4-23
pubmed: 25343186
Cancer Immunol Immunother. 2021 Jan;70(1):169-176
pubmed: 32661686
Neurosurg Rev. 2019 Mar;42(1):163-173
pubmed: 29627874
J Neurooncol. 2019 Apr;142(2):211-221
pubmed: 30656531
JCO Precis Oncol. 2018;2018:
pubmed: 30801050
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
NPJ Genom Med. 2017;2:
pubmed: 28713588
Neuro Oncol. 2017 Jul 1;19(7):986-996
pubmed: 28104717
N Engl J Med. 2017 Oct 12;377(15):1409-1412
pubmed: 29020592
Neuro Oncol. 2019 Jan 1;21(1):26-36
pubmed: 30137421
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Neuro Oncol. 2017 May 1;19(5):625-635
pubmed: 28453751
Front Oncol. 2018 Dec 13;8:612
pubmed: 30619752